Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.

Robert T. Naismith,Jerry S. Wolinsky,Annette Wundes,Christopher LaGanke,Douglas L. Arnold,Dragana Obradovic,Mark S. Freedman,Mark Gudesblatt,Tjalf Ziemssen,Boris Kandinov,Ilda Bidollari,Maria Lopez-Bresnahan,Narinder Nangia,David Rezendes,Lili Yang,Hailu Chen,Shifang Liu,Jerome Hanna,Catherine Miller,Richard Leigh-Pemberton

Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.

2019

Background:Diroximel fumarate (DRF) is a novel oral fumarate for patients with relapsing–remitting multiple sclerosis (RRMS). DRF and the approved drug dimethyl fumarate yield bioequivalent exposur...

Keywords:

Physical therapy
Clinical trial
Bioequivalence
Medicine
Oncology
Multiple sclerosis
Approved drug
Interim
Internal medicine
Dimethyl fumarate
relapsing remitting
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations